Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (Paclitaxel)-induced cytotoxicity

International Journal of Cancer

Volumn 115, Issue 1, 2005, Pages 19-35

  Menendez, Javier A ^a,b,d   Vellon, Luciano ^a,b   Colomer, Ramon ^c   Lupu, Ruth ^a,b  

^a Breast Cancer Translational Res Lab   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d Evanston NW Hlthcare Res Institute ^*  (United States)

Author keywords

Apoptosis; Breast cancer; C75; Chemotherapy; Fatty acid synthase; Paclitaxel; siRNA; Taxol

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA METHYLENE BUTYROLACTONE DERIVATIVE; C75; CERULENIN; DNA FRAGMENT; DOUBLE STRANDED RNA; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; GAMMA BUTYROLACTONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MULTIDRUG RESISTANCE PROTEIN 1; OLIGONUCLEOTIDE; ONCOGENIC ANTIGEN 519; PACLITAXEL; PROTEIN KINASE B; PROTEIN P53; SERINE; SMALL INTERFERING RNA; SYNAPTOPHYSIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CELL STRAIN MCF 7; CELL SURVIVAL; CHEMICAL MODIFICATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAS GENE; GENE; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 17644394237     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20754     Document Type: Article

References (78)

1. Kuhajda FP, Piantadosi S, Pasternack GR. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 1989;321:636-41.
2. Shurbaji MS, Pasternack GR, Kuhajda FP. Expression of haptoglobin-related protein in primary and metastatic breast cancers. A longitudinal study of 48 fatal tumors. Am J Clin Pathol 1991;96:238-42.
3. Jensen V, Holm-Nielsen P, Meisen F. OA-519 expression in node negative breast cancer. Breast Cancer Res Treat 1993;27:1-2.
4. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 1994;91:6379-83.
5. Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage 1 breast carcinoma patients. Cancer 1996;77:474-82.
6. Alo PL, Visca P, Trombetta G, Mangoni A, Lenti L, Monaco S, Botti C, Serpieri DE, Di Tondo U. Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 1999;85:35-40.
7. Alo PL, Visca P, Framarino ML, Botti C, Monaco S, Sebastiani V, Serpieri DE, Di Tondo U. Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 2000;7:1383-8.
8. Gansler TS, Hardman W 3rd, Hunt DA, Schaffel S, Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997;28:686-92.
9. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 1996;27:917-21.
10. Swinnen JV, Vanderhoydonc F, Elgamal AA, Eelen M, Vercaeren I, Joniau S, Van Poppel H, Baert L, Goossens K, Heyns W, Verhoeven G. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 2000;88:176-9.
11. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology Nutrition 2000;16:202-8.
12. Weiss L, Hoffman GE, Schreiber R, Andres H, Fuchs E, Korber E, Kolb HJ. Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty acid synthase. Biol Chem Hoppe Seyler 1986;267:905-12.
13. Ookhtens M, Kannan R, Lyon I, Baker N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol 1984;247:R146-53.
14. Pizer ES, Wood FD, Pasternack GR, Kuhajda FP. Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Res 1996;56:745-51.
15. Omura S. The antibiotic cerulenin: a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bacteriol Rev 1976;40:681-97.
16. Moche M, Schneider G, Edwards P, Dehesh K, Lindqvist Y. Structure of the complex between the antibiotic cerulenin and its target, β-ketoacyl carrier protein synthase. J Biol Chem 1999;274:6031-4.
17. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP. Inhibition of fatty acid synthase induces programmed cell death in human breast cancer cells. Cancer Res 1996;56:2745-7.
18. Pizer ES, Chrest FJ, DiGiuseppe JA, Han WF. Pharmacological inhibition of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 1998;58:4611-5.
19. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA, Kuhajda FP. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000;60:213-8.
20. Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF, Pizer ES. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 2001;61:1493-9.
21. Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP. Inhibition of fatty acid synthase delays disease progression in a xenograft model of ovarian cancer. Cancer Res 1996;56:1189-93.
22. Jochen AL, Hays J, Mick G. Inhibitory effects of cerulenin on protein palmitoylation and insulin internalization in rat adipocytes. Biochim Biophys Acta 1995;1259:65-72.
23. Lawrence DS, Zilfou JT, Smith CD. Structure-activity studies of cerulenin analogues as protein palmitoylation inhibitors. J Med Chem 1999;42:4932-41.
24. Malvoisin E, Wild F. Effect of drugs which inhibit cholesterol synthesis on syncytia formation in vero cells infected with measles virus. Biochim Biophys Acta 1990;1042:359-64.
25. Moelling K, Schulze T, Knoop MT, Kay J, Jupp R, Nicolaou G, Pearl LH. In vitro inhibition of HIV-1 proteinase by cerulenin. FEBS Lett 1990;261:373-7.
26. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 2000;288:2379-81.
27. Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, Finn ML, Ronnett GV, Kuhajda FP. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 2003;63:7330-7.
28. Schiff PB, Fant J, Horwitz. SB. Promotion of microtubule assembly in vitro by Taxol™. Nature 1979;277:665-7.
29. Schiff PB, Horwitz SB. Taxol™ stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77:1561-5.
30. Parness J, Kingston DG, Powell RG, Harracksingh C, Horwitz SB. Structure-activity study of cytotoxicity and microtubule assembly in vitro by Taxol™ and related taxanes. Biochem Biophys Res Commun 1982;105:1082-9.
31. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol™: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;19:646-2.
32. Seidman AD. Single-agent use of Taxol™ (paclitaxel) in breast cancer. Ann Oncol 1994;5(Suppl):S17-22.
33. O'Shaughnessy JA, Cowan KH. Current status of paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat 1995;33:27-37.
34. Hortobagyi GN, Holmes FA. Single-agent paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 1996;23(Suppl):4-9.
35. Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdar AU. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol 1997;24(Suppl):S30-3.
36. Seidman AD, Hudis CA, Raptis G, Baselga J, Fennelly D, Norton L. Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience. Oncology (Huntingt) 1997;11(Suppl):20-8.
37. Bishop JF, Dewar J, Toner GC, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J. Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol™ Investigutional Trials Group, Australia and New Zealand. Oncology (Huntingt) 1997;11(Suppl):19-23.
38. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Huang Y. Taxol™ induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993;7:563-8.
39. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Taxol™-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001;20:147-55.
40. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 1999;83:151-6.
41. Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93-141.
42. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
43. Chou TC, Riedeout D, Chou J, Bertino JR. Chemotherapeutic synergism, potential and antagonism. In: Dulbecco R. eds. Encyclopedia of human biology, vol. 2. San Diego, CA: Academic Press, 1991. 371-379.
44. Chou TC. The median-effect principle and the combination index for quantisation of synergism and antagonism. In: Chou TC, Rideout DC. eds. Synergism and antagonism in chemotherapy. San Diego, CA: Academic Press. 1991. 61-102.
45. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of Taxol™, topotecan and cisplatin against teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-24.
46. Chou J, Chou TC. Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In: Chou TC, Rideout DC, eds. Synergism and antagonism in chemotherapy. San Diego, CA: Academic Press, 1991. 223-244.
47. Dils R, Carey EM. Fatty acid synthase from rabbit mammary gland. Methods Enzymol 1975;35:74-83.
48. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000;101:25-33.
49. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
50. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 2001;114:4557-65.
51. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 2003;63:3799-804.
52. Seidman R, Gitelman I, Sagi O, Horwitz SB, Wolfson M. The role of ERK 1/2 and p38 MAP-Kinase pathways in Taxol™-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res 2001;268:84-92.
53. Deacon K, Mistry P, Chernoff J, Blank JL, Patel R. p38 mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol Biol Cell 2003;14:2071-87.
54. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001;268:2764-72.
55. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
56. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, Fornace AJ Jr. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999;18:6845-54.
57. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-62.
58. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ Jr, Appella E. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002;31:210-5.
59. Damia G, Filiberto L, Vikhanskaya F, Carrassa L, Taya Y, D'incalci M, Broggini M. Cisplatinum and Taxol™ induce different patterns of p53 phosphorylation. Neoplasia 2001;3:10-6.
60. Stewart ZA, Tang LJ, Pietenpol JA. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 2001;20:113-24.
61. Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fornace AJ Jr, Appella E, Anderson CW. Phosphorylation site interdependence of human p53 posttranslational modifications in response to stress. J Biol Chem 2003;278:37536-44.
62. Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-κB. Int J Oncol 2004;24:591-608.
63. MacKeigan JP, Collins TS, Ting JP-Y. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000;275:38953-6.
64. McDaid HM, Horwitz SB. Selective potentiation of paclitaxel (Taxol™)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol 2001;60:290-301.
65. Yu C, Wang S, Dent P, Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol Pharmacol 2001;60:143-54.
66. MacKeigan JP, Taxman DJ, Hunter D, Earp HS 3rd, Graves LM, Ting JP. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of Taxol™ and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 2002;8:2091-9.
67. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:155-99.
68. Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to Taxol™. Oncogene 1998;16:2087-94.
69. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003;63:1515-9.
70. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC. Overexpression of ErbB2 blocks Taxol™-induced apoptosis by upregulation of p21(cip1), which inhibits p34(Cdc2) kinase. Mol Cell 1998;2:581-91.
71. Barboule N, Chadebech P, Baldin V, Vidal S, Valette A. Involvement of p21 in mitotic exist after paclitaxel treatment in MCF-7 breast adenocarcinoma cell lines. Oncogene 1997;15:2867-75.
72. Li W, Fan J, Banerjee D, Bertino JR. Overexpression of p21(waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Mol Pharmacol 1999;55:1088-93.
73. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
74. Blagosklonny MV, Robey R, Bates S and Fojo T: Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 2000;105:533-9.
75. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004;101:10715-20.
76. Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays 2000;22:673-80.
77. Menendez JA, Lupu R, Colomer R. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/neu-overexpressing human breast cancer cells to docetaxel (Taxotere). Breast Cancer Res Treat 2004;84:183-95.
78. Menendez JA, Colomer R, Lupu R. Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncol Rep 2004;12:411-22.